The long-term clinical benefit and effectiveness of switching to once-daily quetiapine extended release in patients with schizophrenia

References

• Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry 2005;50:7-57S
   Google Scholar
• Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005;39:1-30
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Kreyenbuhl J, Kelley DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36:71-93
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (update), National Clinical Practice Guideline Number 82. National Collaborating Centre for Mental Health Commissioned by the National Institute for Health and Clinical Excellence, 2009
   Google Scholar
• Tandon R, Jibson MD. Comparing efficacy of first-line atypical antipsychotics; no evidence of differential efficacy between risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole. Int J Psychiatry Clin Pract 2005;9:204-12
   PubMed Web of Science ®Google Scholar
• Edlinger M, Baumgartner S, Eltanaihi-Furtmüller N, et al. Switching between second-generation antipsychotics: why and how? CNS Drugs 2005;19:27-42
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup S, McEvoy JP, et al., for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Perkins DO, Gu H, Weiden PJ, et al. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry 2008;69:106-13
   PubMed Web of Science ®Google Scholar
• Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open label randomised clinical trial. Lancet 2008;371:1085-97
   PubMed Web of Science ®Google Scholar
• Masand PS, Narasimhan M. Improving adherence to antipsychotic pharmacotherapy. Curr Clin Pharmacol 2006;1:47-56
   PubMedGoogle Scholar
• Birnbaum M, Sharif Z. Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER. Patient Prefer Adherence 2008;2:233-40
   PubMedGoogle Scholar
• Meulien D, Huizar K, Brecher M. Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies. Hum Psychopharmacol 2010;25:103-15
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Brown D, Liu S, et al. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study. Psychopharmacol Bull 2008;41:11-35
   PubMed Web of Science ®Google Scholar
• Kahn RS, Schulz SC, Palazov VD, et al. Study 132 Investigators. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:832-42
   PubMed Web of Science ®Google Scholar
• Peuskens J, Trivedi J, Malyarov S, et al. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients. Psychiatry (Edgmont) 2007;4:34-50
   PubMedGoogle Scholar
• Cutler AJ, Tran-Johnson T, Kalali A, et al. A failed 6-week, randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned. Psychopharmacol Bull 2010;43:37-69
   PubMed Web of Science ®Google Scholar
• Möller HJ, Johnson S, Mateva T, et al. Study 146 Investigators. Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia. Int Clin Psychopharmacol 2008;23:95-105
   PubMed Web of Science ®Google Scholar
• Ganesan S, Agambaram V, Randeree F, et al. Study 147 Investigators. Switching from other antipsychotics to once-daily extended-release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin 2008;24:21-32
   PubMed Web of Science ®Google Scholar
• Järbrink K, Kreif N, Benedict A, et al. Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin 2009;25:709-16
   PubMed Web of Science ®Google Scholar
• Peuskens J, Trivedi JK, Brecher M, et al.; Study 4 Investigators. Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: post-hoc analysis of data from a randomized withdrawal, placebo-controlled study. Int Clin Psychopharmacol 2010;25:183-7
   PubMed Web of Science ®Google Scholar
• El-Khalili N. Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders. Neuropsychiatr Dis Treat 2012;8:523-36
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology. US Institute of Health, 1976
   Google Scholar
• Levine SZ, Rabinowitz J, Engel R, et al. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophrenia Res 2008;98:318-22
   PubMed Web of Science ®Google Scholar
• Leucht S, Kane JM, Etschel E, et al. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006;31:2318-25
   PubMed Web of Science ®Google Scholar
• Andreasen NC. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 2006;113:81
   PubMed Web of Science ®Google Scholar
• AstraZeneca Canada Inc. Seroquel XR Product Monograph. Date of revision: April 2, 2012
   Google Scholar
• Chue P. MacKenzie E, Chue J, et al. The pharmacology and formulation of paliperidone extended release. Exp Rev Neurother 2012;12(2):1399-410
   PubMedGoogle Scholar
• Giegling I, Porcelli S, Balzarro B, et al. Antipsychotic response in the first week predicts later efficacy. Neuropsychobiology 2012;66:100-5
   PubMed Web of Science ®Google Scholar
• Murawiec S, Boutros NN. Correlation between early subjective response to antipsychotics and the number of hospitalizations and hospitalization days in a period of 10–11 years in schizophrenia patients. Neuropsychobiology 2012;66:120-5
   PubMed Web of Science ®Google Scholar
• Levine SZ, Leucht S. Early symptom response to antipsychotic medication as a marker of subsequent symptom change: an eighteen-month follow-up study of recent episode schizophrenia. Schizophr Res 2012;141:168-72
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Lieberman JA, Weiden PJ, et al. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr 2005;10(11 S17):1-20
   PubMedGoogle Scholar
• Remington G, Chue P, Kopala L, et al. Switching atypical antipsychotics: a review. Acta Neuropsychiatrica 2004;16:301-13
   PubMed Web of Science ®Google Scholar
• Alptekin K, Hafez J, Brook S, et al. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Int Clin Psychopharmacol 2009;24:229-38
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Suzuki T, Uchida H, et al. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering. J Clin Psychopharmacol 2008;28:540-3
   PubMed Web of Science ®Google Scholar
• Leucht S, Kane JM, Kissling W, et al. What does the PANSS mean? Schizophr Res 2005;79:231-8
   PubMed Web of Science ®Google Scholar
• Nord M, Nyberg S, Brogren J, et al. Comparison of D2 dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects. Int J Neuropsychopharmacol 2011;14:1357-66
   PubMed Web of Science ®Google Scholar
• Mamo DC, Uchida H, Vitcu I, et al. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry 2008;69:81-6
   PubMed Web of Science ®Google Scholar
• Figueroa C, Brecher M, Hamer-Maansson JE, et al. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:199-204
   PubMed Web of Science ®Google Scholar
• Zhong KX, Sweitzer DE, Hamer RM, et al. Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry 2006;67:1093-103
   PubMed Web of Science ®Google Scholar
• Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001;23:1838-54
   Google Scholar
• Emsley RA, Raniwalla J, Bailey PJ, et al. A comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenic patients with a history of demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 2000;15:121-31
   PubMed Web of Science ®Google Scholar
• Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med 2000;30:95-105
   PubMed Web of Science ®Google Scholar
• Koponen H, Larmo I. Reversal of antipsychotic-induced weight gain during quetiapine treatment. Int Clin Psychopharmacol 2003;18:355-6
   PubMed Web of Science ®Google Scholar
• Deberdt W, Lipkovich I, Heinloth AN, et al. Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder. Ther Clin Risk Manag 2008;4:713-20
   PubMedGoogle Scholar
• Chiu CC, Chen KP, Liu HC, et al. The early effect of olanzapine and risperidone on insulin secretion in atypical-naïve schizophrenic patients. J Clin Psychopharmacol 2006;26:504-7
   PubMed Web of Science ®Google Scholar
• Kryzhanovskaya LA, Xu W, Millen BA, et al. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine. J Child Adolesc Psychopharmacol 2012;22:157-65
   PubMed Web of Science ®Google Scholar
• Bushe CJ, Slooff CJ, Haddad PM, et al. Weight change from 3-year observational data: findings from the worldwide schizophrenia outpatient health outcomes database. J Clin Psychiatry 2012;73:e749-55
   PubMedGoogle Scholar
• Chue P. Metabolic regulation and atypical antipsychotic drugs. In: Atypical antipsychotics: A bench to bedside perspective for clinicians (Eds. J Csernansky, J Lauriello). New York: Marcel Dekker Inc., 2004
   Google Scholar
• Bresee LC, Majumdar SR, Patten SB, et al. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res 2010;117:75-82
   PubMed Web of Science ®Google Scholar
• De Hert M, Dekker JM, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European psychiatric association (EPA), supported by the European association for the study of diabetes (EASD) and the European society of cardiology (ESC). Eur Psychiatry 2009;24:412-24
   PubMed Web of Science ®Google Scholar
• Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res 2009;113:1-11
   PubMed Web of Science ®Google Scholar
• Falissarda B, Maurid M, Shawe K, et al. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. Int Clin Psychopharmacol 2011;26:291-302
   PubMed Web of Science ®Google Scholar
• Lalonde P. Evaluating antipsychotic medications: predictors of clinical effectiveness. Report of an expert review panel on efficacy and effectiveness. Can J Psychiatry 2003;48:3-12S
   PubMedGoogle Scholar
• Streiner DL. The 2 ‘Es’ of research: efficacy and effectiveness trials. Can J Psychiatry 2002;47:552-6
   PubMed Web of Science ®Google Scholar